Inhibitory signaling of 17β-estradiol in platelet activation: The pivotal role of cyclic AMP-mediated nitric oxide synthase activation

Gong-Jhe Wu, Jie Jen Lee, Duen-Suey Chou, Thanasekaran Jayakumar, George Hsiao, Wei Fan Chen, Joen-Rong Sheu

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Arterial thromboses are mostly composed of platelets adherent to ruptured endothelial surfaces. Platelets are anucleated cells; therefore, they represent an excellent and unique model to selectively investigate the signaling pathways mediating the nongenomic effects of estrogen. The aim of this study was to examine the signal transduction pathways of 17β-estradiol in preventing platelet activation. In this study, 17β-estradiol (5~10μM) exhibited more-potent activity of inhibiting platelet aggregation stimulated by collagen than other agonists (i.e., thrombin). 17β-Estradiol-inhibited collagen-stimulated platelet activation accompanied by [Ca2+]i mobilization, thromboxane A2 (TxA2) formation, and phospholipase C (PLC)β2, protein kinase C (PKC), and p38 mitogen-activated protein kinase (MAPK) phosphorylation. 17β-Estradiol markedly increased cyclic AMP and cyclic GMP levels, nitric oxide (NO) release, vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and endothelial nitric oxide synthase (eNOS) expression. SQ 22536, an inhibitor of adenylate cyclase, markedly reversed the 17β-estradiol-mediated effects (i.e., platelet aggregation, and PLCγ2, VASP, and eNOS phosphorylation). Furthermore, ICI 182,780, a pure estrogen receptor antagonist, also reversed the 17β-estradiol-mediated effects on platelet aggregation and eNOS activation. In conclusion, the most important findings of this study demonstrate for the first time that the inhibitory effect of 17β-estradiol in platelet activation involves activation of the cyclic AMP-eNOS/NO-cyclic GMP pathway, resulting in inhibition of PLCγ2 and p38 MAPK activation, which may lower the incidence of cardiovascular events in postmenopausal women.

Original languageEnglish
Pages (from-to)140-149
Number of pages10
JournalEuropean Journal of Pharmacology
Volume649
Issue number1-3
DOIs
Publication statusPublished - Dec 15 2010

Fingerprint

Platelet Activation
Nitric Oxide Synthase
Cyclic AMP
Estradiol
Nitric Oxide Synthase Type III
Platelet Aggregation
Cyclic GMP
Phosphorylation
p38 Mitogen-Activated Protein Kinases
Nitric Oxide
Collagen
Blood Platelets
Thromboxane A2
Type C Phospholipases
Thrombin
Protein Kinase C
Signal Transduction
Estrogens
Thrombosis
Incidence

Keywords

  • 17-γ-Estradiol
  • Cyclic AMP
  • Nitric oxide synthase
  • Phospholipase Cγ2
  • Platelet activation

ASJC Scopus subject areas

  • Pharmacology

Cite this

Inhibitory signaling of 17β-estradiol in platelet activation : The pivotal role of cyclic AMP-mediated nitric oxide synthase activation. / Wu, Gong-Jhe; Lee, Jie Jen; Chou, Duen-Suey; Jayakumar, Thanasekaran; Hsiao, George; Chen, Wei Fan; Sheu, Joen-Rong.

In: European Journal of Pharmacology, Vol. 649, No. 1-3, 15.12.2010, p. 140-149.

Research output: Contribution to journalArticle

@article{1ea40923202f48c88c93e512d9b8ebfd,
title = "Inhibitory signaling of 17β-estradiol in platelet activation: The pivotal role of cyclic AMP-mediated nitric oxide synthase activation",
abstract = "Arterial thromboses are mostly composed of platelets adherent to ruptured endothelial surfaces. Platelets are anucleated cells; therefore, they represent an excellent and unique model to selectively investigate the signaling pathways mediating the nongenomic effects of estrogen. The aim of this study was to examine the signal transduction pathways of 17β-estradiol in preventing platelet activation. In this study, 17β-estradiol (5~10μM) exhibited more-potent activity of inhibiting platelet aggregation stimulated by collagen than other agonists (i.e., thrombin). 17β-Estradiol-inhibited collagen-stimulated platelet activation accompanied by [Ca2+]i mobilization, thromboxane A2 (TxA2) formation, and phospholipase C (PLC)β2, protein kinase C (PKC), and p38 mitogen-activated protein kinase (MAPK) phosphorylation. 17β-Estradiol markedly increased cyclic AMP and cyclic GMP levels, nitric oxide (NO) release, vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and endothelial nitric oxide synthase (eNOS) expression. SQ 22536, an inhibitor of adenylate cyclase, markedly reversed the 17β-estradiol-mediated effects (i.e., platelet aggregation, and PLCγ2, VASP, and eNOS phosphorylation). Furthermore, ICI 182,780, a pure estrogen receptor antagonist, also reversed the 17β-estradiol-mediated effects on platelet aggregation and eNOS activation. In conclusion, the most important findings of this study demonstrate for the first time that the inhibitory effect of 17β-estradiol in platelet activation involves activation of the cyclic AMP-eNOS/NO-cyclic GMP pathway, resulting in inhibition of PLCγ2 and p38 MAPK activation, which may lower the incidence of cardiovascular events in postmenopausal women.",
keywords = "17-γ-Estradiol, Cyclic AMP, Nitric oxide synthase, Phospholipase Cγ2, Platelet activation",
author = "Gong-Jhe Wu and Lee, {Jie Jen} and Duen-Suey Chou and Thanasekaran Jayakumar and George Hsiao and Chen, {Wei Fan} and Joen-Rong Sheu",
year = "2010",
month = "12",
day = "15",
doi = "10.1016/j.ejphar.2010.09.055",
language = "English",
volume = "649",
pages = "140--149",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Inhibitory signaling of 17β-estradiol in platelet activation

T2 - The pivotal role of cyclic AMP-mediated nitric oxide synthase activation

AU - Wu, Gong-Jhe

AU - Lee, Jie Jen

AU - Chou, Duen-Suey

AU - Jayakumar, Thanasekaran

AU - Hsiao, George

AU - Chen, Wei Fan

AU - Sheu, Joen-Rong

PY - 2010/12/15

Y1 - 2010/12/15

N2 - Arterial thromboses are mostly composed of platelets adherent to ruptured endothelial surfaces. Platelets are anucleated cells; therefore, they represent an excellent and unique model to selectively investigate the signaling pathways mediating the nongenomic effects of estrogen. The aim of this study was to examine the signal transduction pathways of 17β-estradiol in preventing platelet activation. In this study, 17β-estradiol (5~10μM) exhibited more-potent activity of inhibiting platelet aggregation stimulated by collagen than other agonists (i.e., thrombin). 17β-Estradiol-inhibited collagen-stimulated platelet activation accompanied by [Ca2+]i mobilization, thromboxane A2 (TxA2) formation, and phospholipase C (PLC)β2, protein kinase C (PKC), and p38 mitogen-activated protein kinase (MAPK) phosphorylation. 17β-Estradiol markedly increased cyclic AMP and cyclic GMP levels, nitric oxide (NO) release, vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and endothelial nitric oxide synthase (eNOS) expression. SQ 22536, an inhibitor of adenylate cyclase, markedly reversed the 17β-estradiol-mediated effects (i.e., platelet aggregation, and PLCγ2, VASP, and eNOS phosphorylation). Furthermore, ICI 182,780, a pure estrogen receptor antagonist, also reversed the 17β-estradiol-mediated effects on platelet aggregation and eNOS activation. In conclusion, the most important findings of this study demonstrate for the first time that the inhibitory effect of 17β-estradiol in platelet activation involves activation of the cyclic AMP-eNOS/NO-cyclic GMP pathway, resulting in inhibition of PLCγ2 and p38 MAPK activation, which may lower the incidence of cardiovascular events in postmenopausal women.

AB - Arterial thromboses are mostly composed of platelets adherent to ruptured endothelial surfaces. Platelets are anucleated cells; therefore, they represent an excellent and unique model to selectively investigate the signaling pathways mediating the nongenomic effects of estrogen. The aim of this study was to examine the signal transduction pathways of 17β-estradiol in preventing platelet activation. In this study, 17β-estradiol (5~10μM) exhibited more-potent activity of inhibiting platelet aggregation stimulated by collagen than other agonists (i.e., thrombin). 17β-Estradiol-inhibited collagen-stimulated platelet activation accompanied by [Ca2+]i mobilization, thromboxane A2 (TxA2) formation, and phospholipase C (PLC)β2, protein kinase C (PKC), and p38 mitogen-activated protein kinase (MAPK) phosphorylation. 17β-Estradiol markedly increased cyclic AMP and cyclic GMP levels, nitric oxide (NO) release, vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and endothelial nitric oxide synthase (eNOS) expression. SQ 22536, an inhibitor of adenylate cyclase, markedly reversed the 17β-estradiol-mediated effects (i.e., platelet aggregation, and PLCγ2, VASP, and eNOS phosphorylation). Furthermore, ICI 182,780, a pure estrogen receptor antagonist, also reversed the 17β-estradiol-mediated effects on platelet aggregation and eNOS activation. In conclusion, the most important findings of this study demonstrate for the first time that the inhibitory effect of 17β-estradiol in platelet activation involves activation of the cyclic AMP-eNOS/NO-cyclic GMP pathway, resulting in inhibition of PLCγ2 and p38 MAPK activation, which may lower the incidence of cardiovascular events in postmenopausal women.

KW - 17-γ-Estradiol

KW - Cyclic AMP

KW - Nitric oxide synthase

KW - Phospholipase Cγ2

KW - Platelet activation

UR - http://www.scopus.com/inward/record.url?scp=78049246328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049246328&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2010.09.055

DO - 10.1016/j.ejphar.2010.09.055

M3 - Article

C2 - 20883689

AN - SCOPUS:78049246328

VL - 649

SP - 140

EP - 149

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -